98%
921
2 minutes
20
Mechanisms by which mucosal regeneration is abrogated in inflammatory bowel disease (IBD) are still under investigation, and a role for an intestinal stem cell (ISC) defect is now emerging. Herein, we report an abnormal ISC death that occurs in Crohn's disease, which exacerbates colitis, limits ISC-dependent mucosal repair, and is controlled through the death factor Transmembrane protein 219 (TMEM219). Large alterations in TMEM219 expression were observed in patients with Crohn's disease, particularly in those with active disease and/or those who were nonresponders to conventional therapy, confirming that TMEM219 signaling is abnormally activated and leads to failure of the mucosal regenerative response. Mechanistic studies revealed a proapoptotic TMEM219-mediated molecular signature in Crohn's disease, which associates with Caspase-8 activation and ISC death. Pharmacological blockade of the IGFBP3/TMEM219 binding/signal with the recombinant protein ecto-TMEM219 restored the self-renewal abilities of miniguts generated from patients with Crohn's disease in vitro and ameliorated DSS-induced and T cell-mediated colitis in vivo, ultimately leading to mucosal healing. Genetic tissue-specific deletion of TMEM219 in ISCs in newly generated TMEM219fl/flLGR5cre mice revived their mucosal regenerative abilities both in vitro and in vivo. Our findings demonstrate that a TMEM219-dependent ISC death exacerbates colitis and that TMEM219 blockade reestablishes intestinal self-renewal properties in IBD.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12077909 | PMC |
http://dx.doi.org/10.1172/JCI185783 | DOI Listing |
Urol Oncol
September 2025
Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
Introduction: The effect of inflammatory bowel disease (IBD) on adverse in-hospital outcomes after radical prostatectomy (RP) for nonmetastatic prostate cancer (PCa) is not well known.
Materials And Methods: Descriptive analyses, propensity score matching and multivariable logistic regression models were used within the National Inpatient Sample (2000-2019) RP patients, after stratification according to Crohn's disease (CD) vs. ulcerative colitis (UC) vs.
Cell Mol Gastroenterol Hepatol
September 2025
Guangdong Provincial Key Laboratory of Gastroenterology, Institute of Gastroenterology of Guangdong Province, Department of Gastroenterology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. Electronic address:
Background & Aims: Over-activation of pyroptosis, recently reidentified as Gasdermin D (GSDMD)-mediated proinflammatory cell death, results in severe inflammation-related disorders. Intestinal fibrosis, an inflammation-related disorder, remains one of the most common and intractable complications of Crohn's disease (CD). However, it is unknown whether excessive pyroptosis contributes to the development of intestinal fibrosis in CD.
View Article and Find Full Text PDFLife Sci
September 2025
KM Convergence Research Division, Korea Institute of Oriental Medicine, Republic of Korea; Korean Convergence Medical Science Major, KIOM School, University of Science & Technology (UST), Daejeon, 34054, Republic of Korea. Electronic address:
Background: Intestinal fibrosis is a severe and progressive complication of inflammatory bowel disease (IBD), particularly Crohn's disease (CD), for which no effective anti-fibrotic therapies currently exist.
Purpose: This study aimed to investigate the anti-fibrotic efficacy and underlying mechanisms of Prim-O-glucosylcimifugin (POG), a natural chromone derivative, in TGF-β1-stimulated human intestinal fibroblasts.
Methods: Fibrosis was modeled in human intestinal fibroblast cell lines (CCD-18Co) and human primary intestinal myofibroblasts (HIMF) using TGF-β1.
United European Gastroenterol J
September 2025
Sheba Medical Center Tel Hashomer, Faculty of Medical and Health Sciences, Gastroenterology Institute, Tel-Aviv University, Tel Aviv, Israel.
Background: Mucosal healing (MH) is a key treatment goal in Crohn's disease (CD). However, evidence on pan-enteric MH (PE-MH) in CD patients treated with vedolizumab remains limited. We aimed to assess vedolizumab efficacy in achieving PE-MH using PillCam Crohn's capsule.
View Article and Find Full Text PDFInflamm Bowel Dis
September 2025
Gut Microbes and Health Programme, Quadram Institute Bioscience, Norwich Research Park, Norwich, United Kingdom.
Background: Intestinal cells receive incoming signals from neighboring cells and microbial communities. Upstream signaling pathways transduce these signals to reach transcription factors (TFs) that regulate gene expression. In inflammatory bowel disease (IBD), most single nucleotide polymorphisms (SNPs) are in non-coding genomic regions containing TF binding sites.
View Article and Find Full Text PDF